Published in Blood Cancer J on February 03, 2017
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood (2010) 1.89
Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell (2009) 1.84
Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood (2013) 1.69
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res (2009) 1.65
Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res (2011) 1.51
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol (2015) 1.29
Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr Protein Pept Sci (2004) 1.28
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell (2012) 1.19
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res (2015) 0.93
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 0.92
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood (2016) 0.90
Enteric pathogens deploy cell cycle inhibiting factors to block the bactericidal activity of Perforin-2. Elife (2015) 0.86
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discov (2015) 0.81
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia (2014) 0.98
The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy. Leukemia (2015) 0.85
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Blood Cancer J (2014) 0.80
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J (2015) 0.75
Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang (2015) 0.75